AbbVie falls as weak aesthetics segment sales overshadow Q3 results beat

Shares of drugmaker AbbVie ABBV.N fall 4.3% at $218.34 in early trading

*Stock is headed for biggest one-day pct loss in over five months, if losses hold

ABBV's sales from its aesthetics products portfolio, which includes anti-wrinkle treatment Botox, fell 3.7% from last year

"Another weaker quarter for the Aesthetics business could raise some eyebrows... continued headwinds mount across products, including Botox and fillers," says BMO Capital Markets analyst Evan Seigerman

AbbVie expects Q4 revenue to be $16.3 billion vs analysts' estimates of $16.33 billion - LSEG data

Co reports Q3 adj. profit of $1.86/shr vs estimates of $1.77/shr

Quarterly revenue of $15.78 billion beats expectations of $15.59 billion

ABBV raises annual profit forecast to $10.61-$10.65/shr from its previous forecast of $10.38-$10.58/shr

Including session's move, stock up ~28% YTD